Skip to Main Content

Paper Details

Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
PLoS One
34
2013
Author NameAffiliation
Diego CadavidMS Clinical Development Group
  • 1 - 1

Datasets

Release 1.2